AMI Plasma Cartridge, AMI
Sequitur Health Corp. · Decision date Sep 1, 2026
What did the FDA decide?
FDA recorded a substantially equivalent (SESE) decision on 2026-09-01 for K260613, a traditional 510(k) submitted by Sequitur Health Corp. of Phoenix, Arizona, and received on 02/25/2026. The device is listed as AMI™ Plasma Cartridge, AMI™, under the classification name Photometric Method, Ammonia, regulation number 862.1065, with primary product code JID and subsequent product code JJE. The review panel and regulation medical specialty are both Clinical Chemistry. SESE indicates clearance to market, not PMA approval.
A separate establishment registration and device listing tied to the same submission names the proprietary products AMI and AMI Plasma Cartridge under product code JJE, classification ANALYZER, CHEMISTRY (PHOTOMETRIC, DISCRETE), FOR CLINICAL USE, regulation 862.2160, device class 1. Sequitur Health Corp. is recorded as manufacturer and complaint file establishment. The source pages do not state the specific component, reagent, or change assessed, the predicate device, or any performance data, so the technical basis for the equivalence finding remains unknown.
The record does not include the decision summary content, indications for use, or labeling, and no clinical or analytical performance conclusions should be drawn from the clearance alone.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Clinical Chemistry
- Decision date
- Sep 1, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K260613
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Sequitur Health Corp.
- Product code
- JID
- Decision code
- SESE
- Decision date
- Sep 1, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Photometric Method, Ammonia.
- Applicant
- Sequitur Health Corp.
- Product code
- JID
- FDA device class
- 1
FDA decision timeline
K260613 received
Application receipt date recorded by FDA.
K260613 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
No additional submissions with a verified PMA or product-code relationship are linked here.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Sequitur Health Corp.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Phoenix, AZ
Sources and methodology
- Original FDA record: K260613
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records